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Abstract
Background and Aim: Urinary aquaporin-2 (AQP2) is a parameter of water transport in
the principal cells in the distal part of the nephron and involved in water retention in cirrho-
sis and may be a marker of renal function. The aim of the study was to evaluate AQP2 as a
predictor of renal insufficiency and death in patients with cirrhosis.
Methods: Urine samples from 199 patients (90 patients without organ failure [Group 1], 58
patients with organ failure excluding renal failure [Group 2], and 51 patients with organ
failure including renal failure [Group 3]) from the CANONIC study were analyzed for
urine AQP2 and urine osmolality.
Results: There was no difference in AQP2 between the three groups. Urine osmolality was
significantly lower in patients in Group 3 versus Group 1 and Group 2 (P = 0.0004). No
relation was found between AQP2 and glomerular filtration rate or creatinine; however,
AQP2 was a significant predictor of the development of renal insufficiency (P = 0.0485).
In a univariate analysis, AQP2 was a significant predictor of 14 and 28-day survival, but
this was not confirmed in multivariate analysis.
Conclusions: Aquaporin-2 was not associated with disease severity or markers of renal
function but was a predictor for the development of renal insufficiency and death. There-
fore, its future use as marker of renal insufficiency could be promising, but further research
is needed before it can be considered a clinical useful tool.
Introduction
Renal failure is a frequent complication in liver cirrhosis, often
precipitated by infections with sepsis, variceal bleeding, or alco-
holic hepatitis. It is a strong marker of poor prognosis.1–3
Early diagnosis of renal impairment and identification of the risk
of renal failure are important unmet clinical needs.
Serum creatinine is widely used but is an inaccurate marker of
glomerular filtration rate (GFR) in cirrhosis.1 The limitations of se-
rum creatinine as a marker of renal function in cirrhosis relate to
the following: 1) a rise in serum creatinine is delayed following in-
jury; 2) creatinine production is decreased in cirrhotic patients be-
cause of malnutrition and muscle wasting; 3) the influence of age,
gender, and ethnicity, 4) increased renal excretion of serum creat-
inine in cirrhosis; and 5) determination of serum creatinine inter-
feres with the level of serum bilirubin.1
Recently, novel biomarkers in serum or urine, such as neutro-
phil gelatinase-associated lipocalin4 and cystatin C,5 reflecting re-
nal function, have been introduced, but prospective studies in
larger patient populations with cirrhosis are still missing. Other
biomarkers that have been investigated in conditions with fluid re-
tention and renal dysfunction in decompensated cirrhosis include
renal water channels such as aquaporin-2 (AQP2).
Aquaporin-2 is located in the collecting ducts in the kidneys and
is regulated by vasopressin thereby controlling water permeability
across the epithelium. AQP2 is recycled and endocytosed; how-
ever, a proportion is excreted in the urine. The excretion is associ-
ated with membrane fragments, small vesicles, and multivesicular
bodies and not whole-cell shedding in rat urine, but the cellular
mechanisms of AQP2 excretion into urine remain unknown.6 Dys-
regulation of AQP2 is seen in several disease entities such as con-
gestive heart failure, syndrome of inappropriate antidiuretic
hormone secretion, and liver cirrhosis.7 In cirrhosis, AQP2 has
been studied in both experimental8–12 and human subjects13–20
with divergent results with regard to the diagnostic and prognostic
value of AQP2.
In this study, we investigated AQP2 as a predictor of renal in-
sufficiency and death, its relation to disease severity, and conven-
tional markers of renal insufficiency in a large cohort of
hospitalized cirrhotic patients.
doi:10.1111/jgh.13641
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Patients and methods
Study population. In the current study, we included 199 pa-
tients previously enrolled in the CANONIC study, a prospective,
observational study, whose main goal was to establish a definition
of acute-on-chronic liver failure (ACLF) in patients with liver cir-
rhosis admitted with an acute decompensation.21 Of the 199 pa-
tients, 90 constituted group 1 (G1) that were randomly selected
from patients included in the study with an acute decompensation
of cirrhosis but without organ failure (group 2 in the CANONIC
study). Group 2 (G2) consisted of 58 randomly selected patients
with organ failure at inclusion but without renal failure. Patients
in this group were originally designated to group 1 in the
CANONIC study. Group 3 (G3) consisted of 51 randomly selected
patients with organ failure at inclusion including renal failure. Pa-
tients in this group were also originally designated to group 1 in
the CANONIC study.
Definitions of organ failure in the CANONIC study were as fol-
lows: a) liver failure was defined as a serum bilirubin level of
12 mg/dL or more; b) kidney failure was defined as a serum creat-
inine level of 2 mg/dL or more, or the use of renal replacement
therapy; c) cerebral failure was defined as grade III or IV hepatic
encephalopathy according to the West Haven criteria; d) coagula-
tion failure was defined as an INR of more than 2.5 and/or platelet
count of 20 × 109/L or less; e) circulatory failure was defined as
the use of dopamine, dobutamine, or terlipressin; f) respiratory
failure was defined as a ratio of partial pressure of arterial oxygen
to fraction of inspired oxygen (FiO2) of 200 or less or a pulse
oximetric saturation (SpO2) to FiO2 ratio of 200 or less.
21
In the CANONIC study,21 clinical and biochemical data were
collected at hospitalization and inclusion (median time between
hospitalization and inclusion 3 days) and at different time points
during hospitalization (days 1, 2, 3–7, 8–14, 15–21, and 22–28 af-
ter inclusion). In this study, we used data from the inclusion visit
for analyses. Mortality data from days 7, 14, 28, and 90 were re-
corded and analyzed. Urine samples were collected 2 days after in-
clusion into the protocol.
The design of the CANONIC study implies that some patients
were admitted because of renal failure, which then was alleviated
before inclusion, while other patients developed renal failure in
the time between admission and inclusion.
Methods. Glomerular filtration rate was calculated using the
following formula:
GFR_MDRD4 ¼ 186creatinine mg=dLð Þ1:154age yearsð Þ0:203
GNFETF;
where GNF = gender factor (male = 1; female = 0.742), ETF = eth-
nicity factor (non-black = 1; black = 1.21).22
In the analysis of AQP2 as a predictor of renal insufficiency, we
retrieved creatinine values at the previously mentioned time
points. If any of the patients at these visits had serum creatinine
levels above 1.5 mg/dL, they were characterized as having renal
insufficiency.
Furthermore, in the analysis of AQP2 as a predictor of renal in-
sufficiency, we applied the recently suggested diagnostic criteria
for acute kidney injury (AKI) in patients with cirrhosis.
Definition of AKI is as follows: increase in serum creatinine
≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 h; or a percentage increase
in serum creatinine ≥ 50% from baseline, which is known, or pre-
sumed, to have occurred within the prior 7 days.1
Lastly, we investigated the impact of the defined organ failures
in the Canonic protocol on AQP2.
Urine samples. Urine samples collected on day 2 after inclu-
sion were analyzed for AQP2 and osmolality.
Urine samples were kept frozen at 20°C until assayed; AQP2
has a half-life of 9–14 h23 and is stable at 20°C for 2 years.6 Uri-
nary AQP2 was measured by radioimmunoassay as previously de-
scribed.24 Antibodies were raised in rabbits to a synthetic peptide
corresponding to the 15 COOH-terminal amino acids in human
AQP2 to which was added an NH2-terminal cysteine for conjuga-
tion and affinity purification. Minimal detection level was
34 pg/tube. The coefficients of variation were 11.7% (inter-assay)
and 5.9% (intra-assay). The anti-AQP2 antibody was a gift from
Søren Nielsen, Department of Biomedicine, Aarhus University,
Denmark.
Plasma and urine osmolality was measured by freezing point de-
pression (Advanced Model 3900 multisampling osmometer).
The CANONIC study was approved by ethical review boards of
all study sites, and all patients enrolled in the study gave written
consent prior to participation.21 The study protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institutions human research
committees.
Statistics. Data were collected from an electronic case report
form.
Results are for the continuous variables given as mean  SD
if normally distributed and median and interquartile ranges if
non-normally distributed. For the categorical variables, results
are given as count and percentage in each category. One-way
analysis of variance and Kruskal–Wallis test were used for
comparison of the continuous variables and Chi-Square test
for the categorical variables. Correlations were performed with
the Spearman’s rank correlation test. For evaluation of AQP2
as a predictor of renal insufficiency and mortality, the Mann–
Whitney test was used for comparison of the two groups.
The Mann–Whitney test was also used to evaluate the impact
of organ failures on AQP2. Seven-day, 14-day, 28-day, and
90-day mortality rates were estimated as transplant-free-
censored mortality using log-rank test to estimate differences
between the three groups and Kaplan–Meier plots to demon-
strate this graphically. The same approach was applied for
the analysis of the differences in AQP2 between the three
groups in 28-day and 90-day survival. Univariate analyses of
28-day and 90-day mortality were performed using t-test and
Mann–Whitney test for continuous variables, normally distrib-
uted and non-normally distributed, respectively. For the cate-
gorical variables, Chi-Square test or Fisher’s exact test was
used. Variables resulting statistically significant in the univari-
ate analysis were included in the multivariate analyses, where
Cox regression analysis was used. A P-value < 0.05 was con-
sidered significant.
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Results
Table 1 shows the demographic, clinical, and biochemical charac-
teristics of the study population. Of the 199 patients included, 121
were men, and the median age was 57 years (range 48–65);
patients in G3 were slightly older than patients in G1 and G2.
Patients in G2 and G3 had more advanced disease based upon
the MELD score, whereas patients in G2 had higher Child–Pugh
score, reflecting the high impact of serum creatinine in the MELD
score.
The reason for hospitalization was mainly ascites, followed by
hepatic encephalopathy, renal failure, bacterial infections, and gas-
trointestinal bleeding. In between the groups, there were more pa-
tients in G3, who were admitted because of bacterial infections,
whereas more patients in G1 were admitted because of gastrointes-
tinal bleeding.
AQP2 and osmolality: distribution and correlation
to creatinine and GFR. There was no significant difference
in urine AQP2 in the three groups (Fig. 1 and Table 2). Further-
more, when patients were stratified into ACLF or not at inclusion
in the study, no difference in AQP2 could be proven: median
AQP2 1.660 ng/mL (Q1–Q3: 1.120–2.950) versus 1.530 ng/mL
(Q1–Q3: 0.805–3.345), P = 0.3776. Likewise, there was no differ-
ence in AQP2 in patients with or without any of the defined organ
failures (renal, coagulation, respiratory, circulatory, or cerebral);
only patients with liver failure had borderline significantly higher
AQP2 than patients without (median AQP2 2.260 ng/mL (Q1–
Q3: 1.300–4.560) versus 1.535 ng/mL (Q1–Q3: 0.875–3.135),
P = 0.0268.
Urine osmolality was significantly lower in G3 compared with
the two other groups (P = 0.0004) (Fig. 2 and Table 2).
Aquaporin-2 showed no significant correlation to either creati-
nine or GFR.
AQP2 and osmolality: relation to mortality. The
mortality risk at 7, 14, 28, and 90 days increased progressively
throughout the three groups (7-day survival, P = 0.0324; 14-day
survival, P = 0.0004; 28-day survival, P = 0.0001; 90-day sur-
vival, P = 0.0006, all Tx-censored, P-value from log-rank test)
with the highest frequencies in G2 and G3 (Fig. 3).
Table 1 Demographic, clinical, and biochemical variables at inclusion
All Patients (n = 199) G1 (n = 90) G2 (n = 58) G3 (n = 51) P-value
Demographic data
Age (years) 57  12 56  12 54  13 60  12 0.0409
Sex (male) 121/199 (61%) 50 (56%) 40 (69%) 31 (61%) 0.2643
Etiology of cirrhosis
Alcohol 102/188 (54%) 39 (47%) 37 (66%) 26 (53%) 0.0844
HCV 36/188 (19%) 20 (24%) 7 (12%) 9 (18%) 0.2310
Alcohol + HCV 22/188 (12%) 11 (13%) 7 (13%) 4 (8%) 0.6631
Miscellaneous 28/188 (15%) 13 (16%) 5 (9%) 10 (20%) 0.2483
Reason for admission
Ascites 131/197 (67%) 62 (70%) 34 (60%) 35 (69%) 0.4265
HE 68/198 (34%) 25 (28%) 23 (40%) 20 (39%) 0.2050
Bacterial infection 42/189 (22%) 13 (15%) 12 (22%) 17 (35%) 0.0253
GI-bleeding 32/195 (16%) 21 (24%) 7 (12%) 4 (8%) 0.0270
Renal failure 58/199 (29%) 11 (12%) 4 (7%) 43 (84%) < 0.0001
Clinical and biochemical data
MAP (mmHg) 81  12 81  11 82  11 80  15 0.6738
HR (bpm) 81  16 81  16 82  14 79  16 0.6134
Hemoglobin (g/dL) 10.1  2.2 10.4  2.3 9.8  1.8 10.1  2.2 0.1952
Platelet count (x103/μL)† 78 (51–125) 95 (58–156) 58 (43–104) 79 (61–143) 0.0007
ALT (U/L)† 32 (21–50) 32 (20–45) 35 (24–51) 30 (19–49) 0.6108
Bilirubin (mg/dL)† 3.0 (1.6–8.2) 2.0 (1.4–4.7) 7.2 (3.4–14.4) 2.6 (1.4–8.3) < 0.0001
Serum albumin (g/dL) 2.9  0.6 2.8  0.6 2.8  0.6 3.0  0.7 0.0700
INR† 1.6 (1.3–2.1) 1.8 (1.4–2.5) 2.7 (2.3–4.7) 2.0 (1.5–4.0) < 0.0001
Alkaline phosphatase (U/L)† 146 (89–213) 146 (102–239) 156 (88–235) 136 (88–190) 0.4935
Liver scores
MELD score 21  8 15  5 24  7 27  8 < 0.0001
Child–Pugh score 10  2 9  2 11  2 10  2 < 0.0001
Results are given as mean  SD or median (Q1 – Q3) if not normally distributed variable = †. P-value from ANOVA or Kruskal–Wallis test if not normally
distributed variable = †.
For categorical variables: n (%). P-value from Chi-Square test.
G1: patients without organ failure at inclusion; G2: patients with organ failure excluding renal failure at inclusion; G3: patients with organ failure includ-
ing renal failure at inclusion.
ALT, alanine transaminase; GI-bleeding, gastrointestinal bleeding; HCV, hepatitis C virus; HE, hepatic encephalopathy; HR, heart rate; MAP, mean ar-
terial pressure; MELD, model for end-stage liver disease.
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In the univariate analysis, AQP2 predicted 14 and 28-day mor-
tality significantly (P = 0.0420 and 0.0322, respectively) where
an increase in AQP2 was related to increased mortality; see
Table 3. However, this was not confirmed in a multivariate analy-
sis. Other factors statistically significant in univariate analysis of
both 28 and 90-day mortality were reason for admission: renal fail-
ure, hemoglobin, bilirubin, INR, serum creatinine, GFR, MELD
score, and Child–Pugh score; see Table 3.
Urine osmolality showed statistical significance as a predictor
of 90-day mortality in univariate analysis (P = 0.004) and
remained significant in a model together with hemoglobin, creat-
inine, and Child–Pugh score in the multivariate analysis; see
Tables 3 and 4.
AQP2 as a predictor of renal insufficiency. Of the
199 patients included, 130 patients had serum creatinine levels be-
low 1.5 mg/dL at inclusion. Of these 130 patients, 22 developed
renal insufficiency, defined as creatinine above 1.5 mg/dL at some
point of time during follow-up. However, baseline AQP2 was un-
able to discriminate patients, who developed renal insufficiency
from patients not developing renal insufficiency: median AQP2
2.430 ng/mL (Q1–Q3: 1.460–3.710) versus 1.385 ng/mL
(Q1–Q3: 0.860–3.820), P = 0.2122.
When we applied the recently suggested diagnostic criteria for
AKI in patients with cirrhosis, 58 patients developed AKI at
some point of time during follow-up. In this analysis, baseline
AQP2 was able to discriminate patients, who developed AKI
from patients who did not: median AQP2 1.870 ng/mL (Q1–
Q3: 1.200–3.550) versus 1.425 ng/mL (Q1–Q3: 0.805–3.250),
P = 0.0485.
Discussion
The main findings of the study were that, in cirrhosis, 1) AQP2
was not related to disease severity, that is there was no difference
in the urinary concentration of AQP2 between the three groups or
between patients with or without ACLF; 2) AQP2 was able to pre-
dict development of renal insufficiency according to recently pro-
posed diagnostic criteria; 3) although AQP2 in a univariate
analysis could predict 14 and 28-day mortality, this did not hold
true in a multivariate analysis; and 4) AQP2 did not correlate with
conventional markers of renal function, that is GFR and serum
creatinine.
The diagnostic criteria of the hepatorenal syndrome (HRS) and
AKI have been debated and revised several times over the years
primarily to improve early identification and correct classification
of renal failure in order to apply focused therapy.1,25–27 Serum
Figure 1 Urine AQP2 levels in G1 (patients without organ failure at in-
clusion), G2 (patients with organ failure excluding renal failure at inclu-
sion), and G3 (patients with organ failure including renal failure at
inclusion). Squares are outliers.
Table 2 Urine AQP2, urine osmolality, and renal parameters at inclusion
All patients (n = 199) G1 (n = 90) G2 (n = 58) G3 (n = 51) P-value
Urine AQP2 (ng/mL)† 1.58 (0.92–3.27) 1.62 (0.82–3.27) 1.71 (1.12–3.79) 1.55 (0.96–2.45) 0.4938
Urine osmolality (mosm/L) 457  168 465  185 507  161 382  110 0.0004
Serum creatinine (mg/dL)† 1.0 (0.7–2.0) 0.9 (0.7–1.1) 0.9 (0.7–1.1) 2.9 (2.4–3.7) < 0.0001
GFR (mL/min/1.73 m2)† 71 (32–105) 90 (66–112) 90 (66–115) 20 (16–27) < 0.0001
Results are given as mean  SD or median (Q1 – Q3) if not normally distributed variable = †. P-value from ANOVA or Kruskal-Wallis test if not normally
distributed variable = †.
G1: patients without organ failure at inclusion; G2: patients with organ failure excluding renal failure at inclusion; G3: patients with organ failure includ-
ing renal failure at inclusion.
GFR, glomerular filtration rate.
Figure 2 Urine osmolality levels in G1 (patients without organ failure at
inclusion), G2 (patients with organ failure excluding renal failure at inclu-
sion), and G3 (patients with organ failure including renal failure at inclu-
sion). Squares are outliers. *P = 0.0004, G3 versus G1 and G2.
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creatinine is still widespread used for clinical assessment of renal
function, although it is a poor marker of especially moderate renal
insufficiency in decompensated cirrhotic patients, where it tends to
overestimate GFR. Moreover, the alternatives, for example creati-
nine clearance based on 24-h urine collection, and more advanced
techniques like 51Cr-EDTA clearance are associated with a num-
ber of disadvantages. Increased tubular creatinine secretion in cir-
rhosis makes estimation of creatinine clearance unreliable, and
moreover, the urine collection is often incomplete. 51Cr-EDTA
clearance is the gold standard of GFR assessment, but because of
complexity in analysis unsuitable for many repeated measurements.2,27
Aquaporin-2 plays a central role in the regulation of free-water
clearance. Its pathophysiological role has been studied in many
diseases, amongst these in cirrhosis with contrasting results.
In animal studies, Fujita et al. and Asahina et al.8,11 found in-
creased levels of AQP2 protein and AQP2 mRNA in rats with
CCl4-induced cirrhosis, whereas Jonassen et al. and Fernandez-
Llama et al. in rats with bile duct ligated-induced cirrhosis showed
decreased expression of AQP2.9,12 The latter group could not in a
later study with rats with CCl4-induced cirrhosis demonstrate any
difference in the abundance of AQP2; however, seemingly, there
was a redistribution of AQP2 indicative of AQP2 trafficking to
the apical plasma membrane, resulting in water retention.10 The
differences found in these animal studies may partly be due to
the ways by which cirrhosis is induced (bile duct ligated vs CCl4).
Ivarsen et al. and Pedersen et al. were the first to describe
changes in AQP2 in cirrhotic patients.15,16 Ivarsen et al. found
an increased excretion of AQP2 in urine in 33 cirrhotic patients
with a progressive increase throughout the Child classes. Patients
were on their usual medication including diuretics as in the present
study. It still needs to be clarified, whether urinary AQP2 excretion
is affected by the intake of diuretics, because one study showed no
effect,28 and others have found the opposite.29 The differences in
findings between the study by Ivarsen et al. and ours may be due
to our patients being divided into groups based on various degrees
of organ failures and not the Child–Pugh score.
Pedersen et al. did not find any difference in AQP2 excretion
between 14 stable cirrhotic patients compared with healthy adults;
in their study, medication was withdrawn 24 h prior to
investigations.16
Esteva-Font et al.13 in 20 cirrhotic patients observed a lower ex-
cretion of AQP2 in urine compared with healthy subjects with a
Figure 3 Ninety-day survival (Tx-censored) by groups of analyses.
P-value (log-rank test) = 0.0006. , G1 (patients without organ failure
at inclusion), , G2 (patients with organ failure excluding renal failure
at inclusion), and , G3 (patients with organ failure including renal
failure at inclusion). [Color figure can be viewed at wileyonlinelibrary.com]
Table 3 Twenty-eight-day and 90-day survival, univariate analysis
28-day mortality 90-day mortality
Alive (n = 181) Dead (n = 18) P-value Alive (n = 156) Dead (n = 40) P-value
Urine AQP2 (ng/mL)† 1.50 (0.89–3.24) 2.32 (1.55–4.2) 0.0322 1.55 (0.89–3.24) 1.77 (1.17–3.47) 0.3747
Urine osmolality (mosm/L) 462  171 404  119 0.1764 469  178 402  107 0.004
Reason for admission: renal failure 48/181 (26%) 10/18 (56%) 0.0097 39/156 (25%) 18/40 (45%) 0.0130
Hemoglobin (g/dL) 10.3  2.1 8.9  2.3 0.0105 10.4  2.2 9.2  1.9 0.001
Bilirubin (mg/dL)† 2.7 (1.5–7.3) 10.6 (3.1–24) 0.0010 2.4 (1.5–7.1) 6.8 (2.6–16.5) < 0.0001
INR† 1.5 (1.3–2.0) 2.1 (1.5–2.6) 0.0029 1.5 (1.3–1.8) 2.1 (1.5–2.6) < 0.0001
Serum creatinine† (mg/dL) 0.9 (0.7–1.9) 2.4 (1.1–3.7) 0.0002 1.0 (0.7–1.8) 1.8 (0.9–3.0) 0.0040
GFR (mL/min/1.73 m2)† 81 (37–109) 29 (19–63) 0.0001 82 (38–110) 37 (20–85) 0.0022
MELD Score 20  7 30  8 < 0.0001 19  7 27  8 < 0.0001
Child–Pugh score 10  2 12  1 0.0017 10  2 11  2 < 0.0001
Results are given as mean SD or median (Q1 – Q3) if not normally distributed variable = †. P-value from T-test or U-Mann–Whitney test if not normally
distributed variable = †.
For categorical variables: n (%). P-value from Chi-Square test.
GFR, glomerular filtration rate; MELD, model for end-stage liver disease.
Table 4 Ninety-day survival, multivariate analysis
Tested variables N (events) HR (95% IC)
Osmolality 162 (31) 0.997 0.995–1.000
Hemoglobin — 0.852 0.726–0.999
Log serum creatinine† — 2.203 1.269–3.824
Child–Pugh score — 1.558 1.280–1.895
†Serum creatinine was log-transformed (Log) in order to follow a normal
distribution.
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progressive decrease in the excretion of AQP2 with increasing dis-
ease severity; patients without ascites had the highest levels of ex-
creted AQP2, followed by patients with ascites and patients with
HRS. In this study, all medication including diuretics was with-
drawn 5 days prior to investigation, while patients were allowed
to drink freely. This standardized condition is however not feasible
in practical daily care.
Chung et al.,17 in coherence with Ivarsen et al., found higher
levels of AQP2 in urine in 81 cirrhotic patients compared with
healthy subjects, and patients with ascites had higher levels com-
pared with patients without ascites. There was no difference in
AQP2 between patients who were kept on medication including
diuretics compared with those where medication was withdrawn
prior to the study.
In our study, AQP2 was not related to disease severity, neither
when based upon our three patient groups, that is patients without
organ failure, with organ failure excluding renal failure, and with
organ failure including renal failure, nor when patients were di-
vided according to having ACLF or not. Furthermore, AQP2
was unable to predict development of death, and it was not related
to conventional markers of renal function. However, AQP2 was
able to predict development of renal insufficiency, although only
borderline significant.
The obvious strength of our study is the prospective design of
the study and the large number of patients included.
Furthermore, patients were not studied in standardized condi-
tions with regards to other conditions, for example hydration status
and cessation of diuretics. This is important, because a biomarker
of renal function should be useful in a clinical setting.
There are many potential reasons for the negative findings in our
study. Dehydration or water deprivation is known to decrease uri-
nary AQP2 excretion.13,15 In our study, the hydration level of the
patients was unknown, and possibly, some patients were
dehydrated. Urinary AQP2 excretion may reflect abundance in re-
nal collecting ducts but not necessarily activity.
Medication that could have influenced AQP2 was not with-
drawn, and most likely, many of the patients in G3 with proba-
ble HRS and possibly those admitted with gastrointestinal
bleeding would have received treatment with vasopressin ana-
logues and human albumin, known to affect the excretion of
AQP2 into urine, although minor.18 Moreover, diuretics were
not withdrawn, which could also have influenced the results,
although the effect on urinary AQP2 excretion has been
questioned.28,29
Furthermore, urine samples were collected up to 2 days after in-
clusion in the study. As ACLF is a very dynamic syndrome,30
these “delays” could have influenced the AQP2 level and thus
blurred the results.
We did not correct for the creatinine concentration in urine. This
would have enabled us to correct for the variation in the volume of
the diuresis that naturally occurs during a 24-h period, which af-
fects the excretion of AQP2 in urine. Another way to come about
this matter is to use the excretion of AQP2 in urine over a certain
time period, which was not possible.
In a clinical perspective, our findings could support the use of
AQP2 as a marker of renal insufficiency in clinical practice, al-
though further research hereof is needed. This would moreover
improve our understanding of the handling of water and sodium
excretion in cirrhosis.18–20
The finding of low urine osmolality to be associated with renal
insufficiency and thereby death is not surprising, because decom-
pensated patients are characterized by their inability to concentrate
their urine. Thus, low urine osmolality is probably a phenomenon
in the established pathophysiology of severe decompensated cir-
rhosis with renal failure.13
In conclusion, AQP2 does predict development of renal insuffi-
ciency but does not correlate to conventional markers of renal in-
sufficiency. Therefore, its future use as a marker of renal
function is unclear, but potentially promising, perhaps in combina-
tion with other markers of renal function such as Cystatin C and
neutrophil gelatinase-associated lipocalin.
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